Musculoskeletal and Neuropathic Pain in COVID-19

Diagnostics (Basel). 2024 Feb 4;14(3):332. doi: 10.3390/diagnostics14030332.

Abstract

Chronic pain constitutes a significant disease burden globally and accounts for a substantial portion of healthcare spending. The COVID-19 pandemic contributed to an increase in this burden as patients presented with musculoskeletal or neuropathic pain after contracting COVID-19 or had their chronic pain symptoms exacerbated by the virus. This extensive literature review analyzes the epidemiology of pain pre-pandemic, the costs associated with the COVID-19 pandemic, the impact of the virus on the body, mechanisms of pain, management of chronic pain post-pandemic, and potential treatment options available for people living with chronic pain who have had or are currently infected with COVID-19.

Keywords: COVID-19; diagnostic challenges; disability; epidemiology; multidisciplinary pain management; musculoskeletal pain; neuropathic pain; new techniques; pain mechanisms; pandemic and impact on pain.

Publication types

  • Review

Grants and funding

A.L.C.’s work on this manuscript was supported in part through funding from the National Institute of General Medical Science, K23GM123320, and the National Institute of Neurological Disorders and Stroke, RM1NS128956. U.L. received funding from Mainstay Medical and Nalu Medical.